Analysts Set Evolent Health, Inc (NYSE:EVH) PT at $11.04

Evolent Health, Inc (NYSE:EVH) has been assigned an average rating of “Moderate Buy” from the sixteen brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $11.0357.

A number of equities research analysts have recently issued reports on EVH shares. BMO Capital Markets began coverage on shares of Evolent Health in a report on Thursday, November 13th. They issued an “outperform” rating and a $7.00 target price on the stock. JPMorgan Chase & Co. dropped their price target on Evolent Health from $13.00 to $7.00 and set an “overweight” rating for the company in a research note on Monday, November 17th. Citizens Jmp decreased their target price on Evolent Health from $13.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Monday, November 10th. Stephens upgraded Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 price target on the stock in a report on Thursday, November 13th. Finally, Canaccord Genuity Group reduced their target price on Evolent Health from $16.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 14th.

Insider Buying and Selling at Evolent Health

In other news, Director Brendan B. Springstubb bought 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were bought at an average cost of $3.82 per share, for a total transaction of $38,200.00. Following the acquisition, the director directly owned 58,821 shares in the company, valued at approximately $224,696.22. This trade represents a 20.48% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Evolent Health

A number of hedge funds have recently bought and sold shares of the company. Brighton Jones LLC purchased a new stake in shares of Evolent Health during the fourth quarter valued at approximately $3,927,000. US Bancorp DE raised its stake in Evolent Health by 291.0% in the first quarter. US Bancorp DE now owns 5,153 shares of the technology company’s stock valued at $49,000 after purchasing an additional 3,835 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Evolent Health by 11.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,023,077 shares of the technology company’s stock worth $9,689,000 after purchasing an additional 104,085 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Evolent Health by 219.1% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 225,370 shares of the technology company’s stock worth $2,134,000 after acquiring an additional 154,753 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Evolent Health by 28.6% in the first quarter. Russell Investments Group Ltd. now owns 98,105 shares of the technology company’s stock worth $929,000 after acquiring an additional 21,826 shares during the period.

Evolent Health Stock Performance

EVH opened at $4.13 on Thursday. The company has a market capitalization of $460.35 million, a price-to-earnings ratio of -2.61 and a beta of 0.28. Evolent Health has a 1 year low of $3.49 and a 1 year high of $12.98. The business’s 50-day moving average price is $5.74 and its two-hundred day moving average price is $8.17. The company has a debt-to-equity ratio of 1.25, a current ratio of 1.33 and a quick ratio of 1.33.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Tuesday, June 4th. The technology company reported $0.21 EPS for the quarter. The business had revenue of $427.70 million for the quarter. Evolent Health had a negative net margin of 6.24% and a positive return on equity of 1.79%. Equities analysts expect that Evolent Health will post 0.08 EPS for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.